Clinical trials
Phase 1 Amyloidosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 6 |
| Recruiting | 4 |
| Withdrawn | 3 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 7 |
| Proclara Biosciences, Inc. | 2 |
| Boston University | 1 |
| Criterium, Inc. | 1 |
| Dartmouth-Hitchcock Medical Center | 1 |
| Eidos Therapeutics, a BridgeBio company | 1 |
| Gracell Biotechnologies (Shanghai) Co., Ltd. | 1 |
| Hadassah Medical Organization | 1 |
| Intellia Therapeutics | 1 |
| Janssen Research & Development, LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyloidosis | 28 |
| Immunoglobulin Light-chain Amyloidosis | 9 |
| Multiple Myeloma | 4 |
| Cardiomyopathies | 2 |
| Alzheimer Disease | 1 |
| Amyloid Neuropathies, Familial | 1 |
| Anemia, Hemolytic, Autoimmune | 1 |
| Cryopyrin-Associated Periodic Syndromes | 1 |
| Heart Failure | 1 |
| Heart Failure, Diastolic | 1 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.